Overview

Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects

Status:
Completed
Trial end date:
2017-12-13
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to investigate the effect of food on the pharmacokinetics of the oral tablet formulation of BI 1015550 by investigating the relative bioavailability of TF1 under fed and fasted conditions. The assessment of safety and tolerability will be an additional objective of this part.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim